Eco Animal Health Group PLC Notice of Results

RNS Number : 0356W

Eco Animal Health Group PLC

11 July 2024

 

11 July 2024

ECO Animal Health Group plc

("ECO" or the "Company")

 

Notice of Results

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that it will issue its financial results for the year ended 31 March 2024 on 15 July 2024.

Investor Presentation

David Hallas, CEO, and Christopher Wilks, CFO, will host a virtual briefing and Q&A session for analysts at 11:00 BST on the day of results.

For further information about the analyst presentation, please contact [e-mail].

-Ends-

For further information please contact:

 

ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO) 020 8447 8899   Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies Sam Butcher 020 7496 3000 Investec (Joint Broker) Gary Clarence Lydia Zychowska 020 7597 5970     Equity Development Hannah Crowe Matt Evans 020 7065 2692 ICR Consilium (Financial PR) Mary-Jane Elliott Jessica Hodgson 020 3709 5700 [e-mail]

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

 

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

 

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NORMZGMNRMKGDZG